Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:

NCT ID: NCT04645368 Completed - Fibroses, Pulmonary Clinical Trials

Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19

Start date: July 1, 2020
Phase:
Study type: Observational

A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of post-inflammatory pulmonary fibrosis and interstitial lung disease following COVID-19.

NCT ID: NCT04631016 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

FRONTIER-4
Start date: December 14, 2020
Phase: Phase 2
Study type: Interventional

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.

NCT ID: NCT04630743 Completed - Heart Failure Clinical Trials

Cognitive and Behavioral Intervention for the Management of Episodic Breathlessness in Patients With Advanced Disease

CoBeMEB
Start date: February 9, 2019
Phase: N/A
Study type: Interventional

Episodic breathlessness is a common and distressing symptom in patients with advanced disease such as cancer, chronic obstructive pulmonary disease (COPD) and chronic heart failure. Since the short duration of the majority of breathless episodes limits the effectiveness of pharmacological interventions (e.g. opioids), non-pharmacological management strategies play a major role. As non-pharmacological strategies patients use, for example, cognitive and behavioural methods such as breathing or relaxation techniques. The aim of the study is to test a brief cognitive and behavioural intervention for an improved management of episodic breathlessness. Initially, a Delphi procedure with international experts has been used to develop the brief intervention consisting of various non-pharmacological strategies to enhance the management of breathless episodes. In the single-arm therapeutic exploratory trial (phase II), the feasibility and potential effects of the brief intervention, such as patient-reported breathlessness mastery, episodic breathlessness characteristics, quality of life, symptom burden, caregivers' burden, and breathlessness in general will be examined. The results of the study form the basis for planning and implementing a subsequent confirmatory randomized control trial (phase III).

NCT ID: NCT04619680 Completed - Clinical trials for Interstitial Lung Disease

The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19

ENDCOV-I
Start date: November 18, 2020
Phase: Phase 4
Study type: Interventional

This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of nintedanib on slowing the rate of lung disease in patients who have been diagnosed with COVID-19, and have ongoing lung injury more than 30 days out from their diagnosis. Required one of the following after diagnosis with SARS-CoV-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as CPAP or BIPAP, or mechanical ventilation or a history of desaturation below 90%.

NCT ID: NCT04614064 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

London Underground Study - Health Effects of Particulate Matter

Start date: August 16, 2021
Phase: N/A
Study type: Interventional

An average of 4.8 million journeys are made on the London Underground every day and as the 'Tube' has elevated airborne particulate matter concentrations compared to ambient air, this raises concern about the potential health impact of this environment. This study explores the health effects of particulate matter from the London Underground on patients with COPD and healthy volunteers. Patients with COPD and healthy participants will be invited to undertake a set 90 min journey on the London Underground, and on a separate occasion (3-8 weeks apart), a 90 min journey on the London Overground (as a proxy for a clean air London area while maintaining other aspects of a train journey). A series of clinical, physiological and inflammatory data will be collected before, during and after (at different time points) each of the sessions in order to compare their response in relation to exposure and/or to disease status.

NCT ID: NCT04606901 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Comparison of Time to Extubation Using Sugammadex or Neostigmine

Start date: April 8, 2021
Phase: Phase 4
Study type: Interventional

A prospective blinded randomized clinical trial to compare time to extubation using Sugammadex versus Neostigmine/glycopyrrolate as reversal agents after use of neuromuscular blockade agents in an outpatient bronchoscopy suite.

NCT ID: NCT04597814 Completed - Clinical trials for the Relationship Between the Tumor Markers and Interstitial Lung Disease Patients

The Relationship Between the Tumor Markers and Interstitial Lung Disease

Start date: January 1, 2019
Phase:
Study type: Observational

The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA125 are often increased in interstitial lung disease patients. This study was undertaken to investigate the source of these serum tumor markers.

NCT ID: NCT04597606 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Respiratory Drive Response in COPD Patients During Exercise With Non Invasive Ventilation (NIV).

HFNIV
Start date: September 2, 2019
Phase:
Study type: Observational

A constant load exercise during 10 minutes will be performed in a group of Chronic Obstructive Pulmonary Disease patients, in a basal condition (spontaneous breathing); under noninvasive mask ventilation and with high flow nasal cannula. With the aim of reducing dyspnea, increasing exercise tolerance, and unload respiratory muscles, three exercises will be compared in terms of use of respiratory muscles and neural drive measured with paraesternal electromyography.

NCT ID: NCT04586946 Completed - Clinical trials for Obstructive Sleep Apnea

FIBRotic Interstitial Lung Disease and Nocturnal OXygen

FIBRINOX
Start date: December 17, 2018
Phase:
Study type: Observational

Home sleep studies - which allow the measurement of breathing while the person sleeps - will be performed on patients with fibrotic interstitial lung disease attending two of the UK's largest respiratory medicine services.The study will investigate at how symptoms, and breathing and exercise tests differ between these two groups after 12 months of study.

NCT ID: NCT04583176 Completed - Pulmonary Disease Clinical Trials

Measurement of Physical Activity in the First Days After Thoracic Surgery

Marchez
Start date: November 16, 2020
Phase:
Study type: Observational

Objective measurement of physical activity has several advantages compared to declarative measures: exemption from memory bias and desirability bias, more precise evaluation, taken into account activities of low intensity, measurement of physical activity and sedentariness profiles (number and duration of periods of activity, number of breaks in sedentary lifestyles). The aim of this study is to assess the early postoperative mobility of patients who have undergone pulmonary excision by thoracoscopy or robot surgery using ActiGraph GT3X accelerometer. This assessment will serve as a reference element for further studies.